SCYNEXIS Discloses Strategic Shift Toward ADPKD Therapeutics Following Asset Acquisition

SCYNEXIS, Inc. (SCYX) discusses transformative asset acquisition and strategic shift towards ADPKD therapeutics. CEO David Angulo highlights the acquisition, which provides access to new assets and technologies. The company is shifting its focus towards developing treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The acquisition is seen as a strategic move to enhance SCYNEXIS' capabilities in this therapeutic area.